Collaboration and licensing agreement for TAVALISSE (fostamatinib disodium hexahydrate)Collaboration and Licensing Agreement • July 11th, 2024
Contract Type FiledJuly 11th, 2024Rigel Pharmaceuticals entered into an exclusive license and supply agreement with Kissei Pharmaceutical to develop and commercialize TAVALISSE in all current and potential indications in Japan, China, Taiwan and the Republic of Korea.